AMRX holder plans Rule 144 stock resale

AMRX filed a notice of proposed resale of common stock under Rule 144.

Rhea-AI Filing Summary

AMRX filed a notice of proposed resale of common stock under Rule 144. The planned sale involves 146,403 shares, all acquired as equity compensation on 03/01/2025, 03/03/2025, and 03/04/2025. The filing lists an approximate sale date of 08/12/2026 and indicates trading on NASDAQ.

Key Figures

Shares planned for resale: 146,403 shares Equity compensation grant 1: 17,973 shares Equity compensation grant 2: 110,904 shares +2 more

5 metrics

Shares planned for resale 146,403 shares Total common stock covered by the Rule 144 notice

Equity compensation grant 1 17,973 shares Common stock acquired on 03/01/2025 via equity compensation

Equity compensation grant 2 110,904 shares Common stock acquired on 03/03/2025 via equity compensation

Equity compensation grant 3 17,526 shares Common stock acquired on 03/04/2025 via equity compensation

Approximate sale date 08/12/2026 Date associated with the planned Rule 144 resale on NASDAQ

Key Terms

Rule 144, equity compensation, common stock

3 terms

Rule 144 regulatory

"filed a notice of proposed resale of common stock under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

equity compensation financial

"shares were acquired as equity compensation on 03/01/2025, 03/03/2025, and 03/04/2025"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

common stock financial

"planned resale of 146,403 shares of common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does AMRX’s Rule 144 filing disclose about planned stock sales?

AMRX’s Rule 144 filing discloses a planned resale of 146,403 shares of common stock. These shares were acquired as equity compensation in early March 2025 and are planned for sale on or about 08/12/2026 on NASDAQ.

How many AMRX shares from equity compensation are covered by this Rule 144 notice?

The Rule 144 notice covers 146,403 shares of AMRX common stock from equity compensation. This total comes from grants of 17,973, 110,904, and 17,526 shares received on 03/01/2025, 03/03/2025, and 03/04/2025 respectively.

When were the AMRX shares planned for Rule 144 sale originally acquired?

The AMRX shares planned for Rule 144 sale were acquired through equity compensation on three dates in 2025. The specific acquisition dates disclosed are 03/01/2025, 03/03/2025, and 03/04/2025, each corresponding to separate common stock awards.

What is the approximate sale date for the AMRX shares in this Rule 144 filing?

The filing lists an approximate sale date of 08/12/2026 for the AMRX common stock. This date reflects when the holder expects to begin reselling the 146,403 equity compensation shares under Rule 144 on the NASDAQ market.

On which market are the AMRX Rule 144 shares expected to be sold?

The Rule 144 disclosure indicates that the AMRX common stock is expected to trade on NASDAQ. The filing ties the proposed resale of 146,403 shares of common stock, acquired via equity compensation, to this exchange listing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 04:18 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001738061
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AMNEAL PHARMACEUTICALS, INC
SEC File Number	001-38485
Address of Issuer	400 CROSSING BLVD, 3RD FLOOR BRIDGEWATER NEW JERSEY 08807
Phone	9089473120
Name of Person for Whose Account the Securities are To Be Sold	NIKITA SHAH
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON STOCK	MERRILL LYNCH 157 CHURCH ST, FL 26 NEW HAVEN CT 06510	146403	2556975	319353919	08/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON STOCK	03/01/2025	EQUITY COMPENSATION	ISSUER			17973	03/01/2025	EQUITY COMPENSATION
COMMON STOCK	03/03/2025	EQUITY COMPENSATION	ISSUER			110904	03/03/2025	EQUITY COMPENSATION
COMMON STOCK	03/04/2025	EQUITY COMPENSATION	ISSUER			17526	03/04/2025	EQUITY COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	NIKITA SHAH
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)